New Zealand Patent System

Fonterra Co-operative Group Limited (Auckland — farmer-owned cooperative; world's largest exporter of dairy products; approximately NZ$22–24 billion revenue) and the broader New Zealand dairy industry generate significant bioprocessing and dairy technology IP: (1) Fonterra's IP strategy: Fonterra is the world's largest dairy exporter and a major processor of milk powder, butter, cheese, and dairy ingredients. Fonterra files patents primarily via PCT and EPO/USPTO for its most significant innovations. Key patent areas: dairy protein fractionation technology (whey protein isolate [WPI], whey protein concentrate [WPC], α-lactalbumin/β-lactoglobulin fractionation using membrane filtration/chromatography — functional dairy ingredients for sports nutrition, infant formula, food fortification; patent-protected separation and processing methods); advanced UHT (Ultra High Temperature) processing patents for dairy beverages and cream products; encapsulation technology patents for probiotics (microencapsulation protecting Lactobacillus/Bifidobacterium strains through GI transit for dairy probiotic products); infant formula production process patents (lactoferrin enrichment, human milk oligosaccharide [HMO] supplementation, hypoallergenic formulas using enzymatic hydrolysis); lactoferrin — Fonterra is the world's largest producer of bovine lactoferrin (antimicrobial iron-binding glycoprotein in milk); lactoferrin isolation and purification process patents; lactoferrin applications in infant formula, dietary supplements, cosmetics; animal growth factor (AGF) technology patents for dairy bioactive compounds; (2) A2 Milk Company (Auckland and Melbourne — NZX and ASX listed; ~NZ$1.5B revenue): A2 Milk holds IP in: genetic screening patents for identifying A2 β-casein cattle (cows that produce milk containing only the A2 protein variant rather than A1+A2); A2 milk production and verification methodology patents; A2 infant formula processing patents; A2 protein's claim to be easier to digest than A1+A2 mixed milk is the commercial foundation; A2 Milk's patents are fundamental to its product differentiation; (3) Other NZ food and agriculture IP: Zespri International (Mount Maunganui — kiwifruit marketer for NZ growers; Zespri SunGold [yellow kiwifruit — the Sungold variety G3 = Actinidia chinensis var. chinensis 'Zesy002' — is protected by plant breeders' rights globally, not a patent; however Zespri actively enforces its plant variety protection rights internationally against unauthorized cultivation — notably against Italian growers who illegally planted G3 in Italy]; Zespri's plant variety protection for G3 is the foundation of its business model); Silver Fern Farms (Dunedin — NZ's largest beef and sheep meat company; meat quality grading technology; value-added product innovation patents); Synlait Milk (Selwyn — advanced dairy processing; infant formula patents for specialized nutritional compositions); Bega Cheese (Australian, with NZ operations — NZ joint venture); (4) Biotech: Douglas Pharmaceuticals (Henderson — generics + specialty pharma; formulation patents); Auckland UniServices (University of Auckland tech transfer office — biotech patent activity from UoA research; cancer biology, vaccine development, marine natural products); Callaghan Innovation (Crown Entity, Lower Hutt — NZ's national innovation accelerator; supports R&D tax credits + research partnerships for NZ companies with patent potential).

New Zealand's technology IP extends beyond medical devices into electronics, software, and precision engineering: (1) Gallagher Group (Hamilton — privately owned; founded by Sir William Gallagher; one of New Zealand's most recognized industrial IP stories): Gallagher invented the modern electric fence energizer. The story is frequently cited in IP education: William Gallagher Sr. built the world's first practical electric fence energizer in 1938 from a car ignition coil and alarm clock mechanism — a solution to the problem of cattle short-circuiting traditional electric fences in wet conditions. The electric fence energizer design and subsequent improvements were the foundation of an agricultural electronics company. Today, Gallagher Group operates in: agricultural technology (electric fence systems — Gallagher Fence® electric fence energizers, smart fence monitoring, animal management software), security systems (Gallagher Security — access control systems [biometric, card-based, mobile credential], perimeter security — second-largest business unit), and healthcare (Gallagher Healthcare — supply chain, asset tracking). Patent activity: IoT-connected fence monitoring patents; biometric access control patents; RFID-based animal management patents (livestock tracking, weigh station integration); smart perimeter security systems; (2) Xero Limited (Wellington — NZX and ASX listed, ~NZ$2B+ revenue, ~4 million subscribers globally): Xero holds cloud accounting software patents and technology IP, but Xero's strategy is primarily trade secret + copyright + first-mover advantage rather than an extensive patent portfolio. Notable IP: cloud-based accounting ledger synchronization technology patents (real-time bank transaction reconciliation algorithms, multi-currency reconciliation); API integration framework patents for connecting to banks, payment systems, and third-party accounting apps; machine learning bank categorization patents (automatic transaction coding AI); Xero's patent strategy is relatively limited compared to its software innovation because of the challenges of software patentability; (3) Rocket Lab (Auckland + Long Beach, CA — NASDAQ listed; small satellite launch vehicles): Rocket Lab is New Zealand's most globally significant space technology company: Electron rocket (aluminum/carbon fiber structure; Rutherford engine — world's first production 3D-printed rocket engine [made via direct metal laser sintering DMLS; turbopump + combustion chamber]; Archimedes engine for Neutron; propulsion system patents); Launch Complex 1 on the Māhia Peninsula (NZ's only commercial orbital launch site); Neutron reusable medium-lift rocket (in development — patents for reusable propulsion architecture, fairing recovery); small satellite constellation deployment patents; Photon spacecraft bus patents; significant US patent activity via USPTO (Rocket Lab US operations); (4) Weta Workshop / Weta FX (Miramar, Wellington — Peter Jackson's visual effects, prosthetics, props): Weta has developed significant IP in motion capture, visual effects technology, 3D scanning, and animatronics. Patent activity in: high-resolution motion capture suits and sensor fusion (The Volume LED stage technology for real-time visual effects); digital human rendering technology; underwater camera housing systems; bionic prosthetics R&D (Weta Workshop's Wētā medical devices subsidiary); (5) THL Group (Hamilton — tourism and automotive; tourism vehicle rentals [maui, Britz]); (6) Fisher & Paykel Appliances (now Haier — Auckland; sold to Haier China 2012): formerly New Zealand's domestic appliance IP center; DishDrawer® dishwasher patents (dual-drawer dishwasher design unique to Fisher & Paykel before Haier acquisition) now part of Haier global IP; separate from Fisher & Paykel Healthcare which retained independent listed status.

The Patents Act 2013 (in force September 13, 2014) introduced the most significant NZ patent law reform in 60 years, with several distinctive provisions: (1) Software patents (§ 11): The 2013 Act explicitly states that a computer program 'as such' is not a patentable invention. This was a deliberate policy decision to protect NZ's software development SME sector from patent suits, particularly from large overseas patent holders. However, the word 'as such' is doing significant work: IPONZ and NZ courts must determine when software is 'software as such' (excluded) vs. a patentable invention implemented in software (potentially patentable). Guidance from IPONZ states: if the invention is a method or process, and if you remove the computer program from the claim, if you no longer have an invention, it is likely 'software as such' and excluded. The NZ software exclusion is stricter than Australia's (which allows computer-implemented inventions under the patentable subject matter test after Aristocrat Technologies v. Commissioner of Patents 2022 — but subsequent Alice-type analysis applies) and somewhat stricter than EPO's technical character approach; (2) Methods of medical treatment (§ 15): Under the Patents Act 1953, methods of medical treatment of human beings WERE patentable in New Zealand — this was different from most Commonwealth countries and from EPO practice. The Patents Act 2013 reversed this: methods of treatment of human beings by surgery, therapy, or diagnostic methods practised on the human body are explicitly NOT patentable. The medical device or drug itself (the product) remains patentable; only the clinical methods are excluded. This aligns NZ with Australian, UK, and EPO practice; (3) Māori Advisory Committee: The 2013 Act established a Māori Advisory Committee to advise the Commissioner of Patents on whether the grant of a patent would be contrary to Māori values (under § 275 of the Patents Act 2013). If an application relates to Māori knowledge, traditions, or culture, IPONZ refers it to the Committee. If the Committee advises that the patent would be offensive to Māori, the Commissioner may decline the application. This is a unique feature of New Zealand patent law not found in other common law jurisdictions — it reflects the Treaty of Waitangi obligations and New Zealand's bicultural legal framework. No patent has reportedly been refused under § 275 as of recent years, but the provision exists as a substantive safeguard; (4) Essentially biological processes (§ 15[3A]): like most developed patent systems (consistent with TRIPS Art. 27.3[b]), essentially biological processes for producing plants or animals are excluded from patentability; (5) Absolute novelty — no grace period: under the 2013 Act, the standard is absolute novelty. The only narrow exception for unauthorized disclosures (where the applicant did not consent to the disclosure) is designed for breach of confidence / confidential disclosure situations, not for the inventor's own intentional public disclosures. NZ's approach is closer to EPC absolute novelty than to US AIA grace period law.

No — New Zealand does not have a general grace period for patent applications under the Patents Act 2013. The Act requires absolute novelty: any public disclosure of the invention before the filing date (or priority date if a Paris Convention or PCT priority is claimed) destroys novelty and makes the invention unpatentable in New Zealand. There is one narrow exception in the 2013 Act: if the disclosure was made WITHOUT the applicant's consent — for example, a breach of a confidentiality obligation, an unauthorized publication by a co-inventor, or a leak of information — and the applicant files within 12 months of that unauthorized disclosure, the disclosure may be excused. This exception is specifically for unauthorized disclosures, not for the inventor's own intentional public disclosures. The practical rule for New Zealand: if you are an inventor seeking New Zealand patent protection, you must file your patent application (whether at IPONZ directly, as a PCT application, or claiming Paris Convention priority from an earlier national filing) BEFORE any public disclosure of the invention. This includes: conference presentations; academic journal publications (even 'pre-prints'); product demonstrations or product launches; investor pitch presentations to non-confidential audiences; press releases; social media posts describing the invention; trade show demonstrations; this contrasts significantly with United States patent law, where AIA § 102(b)(1)(A) gives inventors a 12-month grace period for their own prior disclosures — a US inventor can present at a conference and file within 12 months. That same strategy, if not paired with a patent filing before disclosure, would permanently destroy New Zealand patent rights. The Paris Convention strategy to preserve NZ rights: if an inventor first files a US provisional patent application, and the public disclosure happens after the US provisional filing date, then the inventor can file at IPONZ (or PCT designating NZ) within 12 months of the US provisional filing, claiming the US provisional's filing date as the priority date. Since the priority date predates the public disclosure, NZ novelty is preserved. This is the correct international filing strategy for inventors who need both US and NZ patent protection.

New Zealand and Australia have taken diverging paths on computer software patent eligibility, despite their shared legal heritage, following the New Zealand Patents Act 2013 reform: (1) New Zealand's explicit exclusion: Section 11 of the Patents Act 2013 states: 'A computer program is not a patentable invention.' The phrase 'as such' is the crucial limitation: 'A computer program is not a patentable invention' only covers computer programs as such — meaning software that does nothing beyond standard software functions. IPONZ's test for whether something is a computer program 'as such': if you remove the computer program from the claimed invention, is there still an invention? If the answer is no — the invention only exists in the software itself — then it is a computer program 'as such' and is excluded. If removing the computer program leaves a technical process, device, or system that produces a technical result beyond ordinary software function, the invention may still be patentable (the computer program is a means to the patentable end, not the invention itself); (2) Why New Zealand chose this approach: the Parliamentary debates around the 2013 Act explicitly discussed protecting New Zealand's growing software and IT sector from patent infringement risks (particularly from overseas patent holders). Parliament decided that software patents in particular were creating barriers to NZ software companies rather than incentivizing innovation. The select committee recommended the software exclusion after significant public debate; (3) Australia's different trajectory: Australia's Patents Act 1990 has no equivalent explicit exclusion for software. Australia has navigated the question through case law: Research Affiliates LLC v. Commissioner of Patents (2014) — Full Federal Court affirmed that computer-implemented financial data analysis was not patent-eligible (abstract idea); Commissioner of Patents v. RPL Central Pty Ltd (2015) — Full Federal Court applied a 'manner of manufacture' test rejecting pure business methods implemented in software; Aristocrat Technologies Australia Pty Ltd v. Commissioner of Patents (2022) — Full Federal Court reversed a lower court decision, holding that a gaming machine with a computer-implemented feature was patent-eligible as a 'manner of manufacture' under the Statute of Monopolies. The Aristocrat decision created significant controversy in Australia — it means some computer-implemented inventions are patentable in Australia that would not be in NZ; (4) EPO comparison: the EPO's 'technical character' doctrine (EPC Art. 52[2] — programs for computers 'as such' excluded; but technical character required) is conceptually similar to NZ's 'as such' exclusion but with decades of EPO case law building out the technical character doctrine; (5) US comparison: the US Alice/Mayo framework applies a two-step test for software: (a) is the claim directed to an abstract idea? (b) if so, does the claim contain an 'inventive concept' — something 'significantly more' than the abstract idea? This has created significant uncertainty at the USPTO and in US courts. Some software patents granted in the US would not be patentable in NZ; (6) Practical implication: a New Zealand software startup should focus on whether their innovation produces a specific technical result or process improvement (beyond just 'running software') when structuring patent claims at IPONZ.

Fisher & Paykel Healthcare (FPH) is New Zealand's most globally significant medical device patent holder and one of the world's leading innovators in respiratory humidification technology. Understanding FPH's patent position requires understanding the clinical problem it solves: (1) The clinical need: when patients breathe through mechanical ventilators, CPAP machines, or high-flow oxygen systems, the delivered gas (air or oxygen) is typically cool and dry. Breathing dry gas for extended periods causes: airway mucosal damage (the mucus-secreting and ciliated cells in the trachea/bronchi are damaged by dehydration); secretion inspissation (mucus becomes thick and hard to clear, leading to mucus plugging and atelectasis); patient discomfort (dry throat, nose bleeds, discomfort) reducing CPAP compliance for obstructive sleep apnea patients; FPH's humidification systems solve this by adding heated, humidified air to respiratory therapy devices; (2) FPH's core patent categories: humidifier chamber design patents (the water chamber architecture — materials, geometry, evaporation surface area design — that efficiently humidifies airflow without condensation in the circuit); heated breathing circuit patents (EVAQUA heating wire system in breathing tube — electrical heating wire running through the expiratory limb and inspiratory limb prevents condensation in the circuit, a key problem called 'rainout'; temperature control system patents for maintaining circuit at body temperature); CPAP mask and interface patents (mask cushion geometry, minimal contact nose pillows, full-face masks for different facial anatomies — these are licensed and sold under FPH's brand); Optiflow High Flow Nasal Cannula (HFNC) patents — the nasal cannula interface design for delivering high-flow heated humidified air (up to 60L/min) to spontaneously breathing patients; HFNC is used in: acute hypoxic respiratory failure (alternative to intubation); COVID-19 pneumonia; COPD exacerbations; weaning from mechanical ventilation; the interface (nasal prongs geometry, flow resistance, comfort features) and system integration (Airvo standalone humidifier for Optiflow, MR850 heated humidifier for ventilated patients) are both patented; (3) Competitive landscape: FPH competes in humidification primarily with: ResMed (San Diego — CPAP market leader; FPH and ResMed have been in extensive patent litigation regarding CPAP masks, humidifiers, and algorithms); Philips Respironics (Amsterdam/Pittsburgh — formerly Philips Respironics, now divested following recall crisis); Vapotherm (US — alternative HFNC technology); (4) NZ IP filings: FPH files at IPONZ and uses IPONZ as a home-country base for PCT filings, but the commercially significant patent protection is via USPTO and EPO — NZ is a small percentage of global FPH revenue. The NZ filing is the origin point for PCT international applications; (5) COVID-19 and patent decisions: during COVID-19, FPH and other respiratory equipment manufacturers faced pressure (and some voluntary pledges) to share IP to increase production. FPH contributed to manufacturing scale-up discussions but its specific licensing position under COVID emergency was not publicly disclosed as a formal compulsory license situation.

New Zealand's Patents Act 2013 established a Māori Advisory Committee (Te Rōpū Māori) as a unique feature of the New Zealand patent system reflecting New Zealand's obligations under the Treaty of Waitangi and its recognition of Māori intellectual and cultural heritage: (1) Legal basis and function: Section 275 of the Patents Act 2013 provides: if the Commissioner of Patents considers that a patent application relates to a traditional Māori knowledge or a Māori cultural property, the Commissioner must refer the application to the Māori Advisory Committee (MAC). After considering the application, the MAC must advise the Commissioner on: whether the invention is derived from Māori traditional knowledge, mātauranga Māori, or Māori cultural property; whether the grant of the patent would be contrary to Māori values (tikanga Māori); the Commissioner takes the MAC's advice into account in deciding whether to grant the patent. If the MAC advises that grant of the patent would be contrary to Māori values and would be offensive to Māori, the Commissioner may refuse the application; (2) Who is on the MAC: the Māori Advisory Committee is appointed by the Minister of Commerce and Consumer Affairs. Members are typically experts in Māori culture, te reo Māori (Māori language), mātauranga Māori (Māori knowledge systems), and Treaty of Waitangi issues; (3) Practical operation: the Commissioner refers applications to the MAC when they appear to relate to Māori traditional knowledge. This might include applications relating to: traditional Māori medicines or rongoā (plant-based traditional medicines); cultivation methods of taonga plants (plants of special cultural significance to Māori); Māori symbols, carving patterns, or cultural elements; extraction or use of native New Zealand species associated with Māori culture; (4) Has the MAC refused any patents?: As of publicly available information through 2024, no patent application has been conclusively refused solely on grounds of the MAC's advice that it would be contrary to Māori values. The MAC has considered and commented on a number of applications, and its advice has influenced how applications are presented or whether applicants voluntarily amended claims, but the mechanism has not yet produced a definitive refusal in public jurisprudence; (5) International context: New Zealand's MAC is unique in the common law patent world. No other common law patent system (Australia, Canada, UK, US) has a formal statutory mechanism for indigenous advisory review of patent applications as part of the examination procedure. The World Intellectual Property Organization (WIPO) has discussed traditional knowledge protection in the context of the Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC), but no binding international treaty on traditional knowledge protection has been concluded. New Zealand's MAC is therefore a genuinely unique domestic implementation of indigenous cultural IP protection that has attracted international academic interest.

The Gallagher Group story is frequently cited in New Zealand IP education as an example of practical invention leading to global commercial success — a 'kiwi inventor' narrative that resonates in a country where agricultural innovation is a source of national identity: (1) The problem: in early 20th century New Zealand farming, electric fences were used to confine livestock, but they had a persistent problem: when cattle touched a fence in wet conditions (and New Zealand's climate means frequent wet conditions), their damp hooves and bodies created low-resistance paths to ground, effectively short-circuiting the electric fence — too much current dissipated and the voltage dropped to the point where the fence no longer deterred stock effectively. Traditional fence energizers of the era were continuous-current devices that could not cope with this shorting problem; (2) The invention: William Gallagher Sr. (1897–1967), a Hamilton farmer, approached this problem practically in the late 1930s. He built the world's first practical pulsed electric fence energizer using surplus parts — reportedly using a Ford Model T ignition coil and an alarm clock mechanism as a timer. The key innovation was making the fence pulsed (intermittent current rather than continuous) at approximately 1-second intervals. A pulsed fence energizer: delivers a brief high-voltage pulse (sufficient to deter stock) rather than continuous current; between pulses, the circuit can 'recover' from any short-circuit path through wet vegetation or damp livestock; uses far less power per deterrent shock, allowing battery-powered operation in remote paddocks; the first commercial version was marketed in 1938. The company began as Gallagher Engineering and eventually grew into the Gallagher Group; (3) The patent context: the original Gallagher innovations from the 1930s–1940s are long since in the public domain. The commercial significance of Gallagher's IP today lies in: subsequent generations of improvements (microprocessor-controlled energizer patents; solar-powered energizer systems; precision timing circuits; fault detection systems); IoT-connected fence monitoring — Gallagher's Smart Fence system connects energizers to the internet, allowing remote monitoring of fence voltage, fault location, and livestock breach alerts via smartphone; biometric access control — Gallagher's Security division holds significant patents in multi-credential biometric access control systems; RFID livestock management — electronic ear tag reading systems for automated animal management; (4) Why the story matters for IP: the Gallagher story illustrates several IP principles: a practical, agricultural-sector invention from a farm workshop became a global technology company; the original IP value has long expired, but continuous R&D and follow-on patents sustained competitiveness; New Zealand's agricultural technology IP — Gallagher, Fisher & Paykel Healthcare (medical devices from dairy equipment origins), A2 Milk (dairy genetics) — reflects the country's underlying strength in applied, practical innovation from its core industries.